Charles River Labs forks over $380M cash for cell therapy player; Axsome soars on PhIII depression readout
→ Cell therapy R&D is hot, and Charles River Labs $CRL knows it. The CRO is paying $380 million to acquire …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
